Plasma and Urine Indoleamine 2,3-Dioxygenase Activity: Promising Biomarkers for Chronic Kidney Disease and Inflammation Status

References

• Zhang L, Wang F, Wang L., et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–822. doi:10.1016/S0140-6736(12)60033-6
   PubMed Web of Science ®Google Scholar
• Huang CW, Wee PH, Low LL, et al. Prevalence and risk factors for elevated anxiety symptoms and anxiety disorders in chronic kidney disease: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2021;69:27–40. doi:10.1016/j.genhosppsych.2020.12.003
   PubMed Web of Science ®Google Scholar
• Wee HL, Seng BJ, Lee JJ, et al. Association of anemia and mineral and bone disorder with health-related quality of life in Asian pre-dialysis patients. Health Qual Life Outcomes. 2016;14(1):94. doi:10.1186/s12955-016-0477-8
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 2016;37(3):193–207. doi:10.1016/j.it.2016.01.002
   PubMed Web of Science ®Google Scholar
• Thüring M, Knuchel R, Picchetta L, et al. The prognostic value of indoleamine-2,3-dioxygenase gene expression in urine of prostate cancer patients undergoing radical prostatectomy as first treatment of choice. Front Immunol. 2020;11:1244. doi:10.3389/fimmu.2020.01244
   PubMed Web of Science ®Google Scholar
• Huttunen R, Syrjänen J, Aittoniemi J, et al. High activity of indoleamine 2,3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients. Shock. 2010;33(2):149–154. doi:10.1097/SHK.0b013e3181ad3195
   PubMed Web of Science ®Google Scholar
• Pan B, Zhang H, Hong Y, et al. Indoleamine-2,3-dioxygenase activates wnt/β-catenin inducing kidney fibrosis after acute kidney injury. Gerontology. 2021;67(5):611–619. doi:10.1159/000515041
   PubMed Web of Science ®Google Scholar
• Zhang C, Björkman A, Cai K, et al. Impact of a 3-months vegetarian diet on the gut microbiota and immune repertoire. Front Immunol. 2018;9:908. doi:10.3389/fimmu.2018.00908
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ruan Y, Zhang P, et al. Increased indoleamine 2,3-dioxygenase activity in type 2 diabetic nephropathy. J Diabetes Complications. 2017;31(1):223–227. doi:10.1016/j.jdiacomp.2016.08.020
   PubMed Web of Science ®Google Scholar
• Schefold JC, Zeden JP, Fotopoulou C, et al. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant. 2009;24(6):1901–1908. doi:10.1093/ndt/gfn739
   PubMed Web of Science ®Google Scholar
• Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713–735. doi:10.1053/j.ajkd.2014.01.416
   PubMed Web of Science ®Google Scholar
• Wang W, Huang L, Jin JY, et al. A validation study on IDO immune biomarkers for survival prediction in non-small cell lung cancer: radiation dose fractionation effect in early-stage disease. Clin Cancer Res. 2020;26(1):282–289. doi:10.1158/1078-0432.CCR-19-1202
   PubMed Web of Science ®Google Scholar
• Adu-Gyamfi C, Savulescu D, Mikhathani L, et al. Plasma kynurenine-to-tryptophan ratio, a highly sensitive blood-based diagnostic tool for tuberculosis in pregnant women living with Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2021;73(6):1027–1036. doi:10.1093/cid/ciab232
   PubMed Web of Science ®Google Scholar
• Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis. 2014;63(5):820–834. doi:10.1053/j.ajkd.2013.12.006
   PubMed Web of Science ®Google Scholar
• Platten M, Nollen EAA, Röhrig UF, et al. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019;18(5):379–401. doi:10.1038/s41573-019-0016-5
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018;14(8):493–507. doi:10.1038/s41581-018-0023-5
   PubMed Web of Science ®Google Scholar
• Matheus LHG, Simão GM, Amaral TA, et al. Indoleamine 2, 3-dioxygenase (IDO) increases during renal fibrogenesis and its inhibition potentiates TGF-β 1-induced epithelial to mesenchymal transition. BMC Nephrol. 2017;18(1):287. doi:10.1186/s12882-017-0702-7
   PubMed Web of Science ®Google Scholar
• Čepcová D, Kema IP, Sandovici M, et al. The protective effect of 1-methyltryptophan isomers in renal ischemia-reperfusion injury is not exclusively dependent on indolamine 2,3-dioxygenase inhibition. Biomed Pharmacother. 2021;135:111180. doi:10.1016/j.biopha.2020.111180
   PubMed Web of Science ®Google Scholar
• Torosyan R, Huang S, Bommi PV, et al. Hypoxic preconditioning protects against ischemic kidney injury through the IDO1/kynurenine pathway. Cell Rep. 2021;36(7):109547. doi:10.1016/j.celrep.2021.109547
   PubMed Web of Science ®Google Scholar
• Walker JA, Richards S, Whelan SA, et al. Indoleamine 2,3-dioxygenase-1, a novel therapeutic target for post-vascular injury thrombosis in CKD. J Am Soc Nephrol. 2021;32(11):2834–2850. doi:10.1681/ASN.2020091310
   PubMed Web of Science ®Google Scholar
• Ketelhuth DFJ. The immunometabolic role of indoleamine 2,3-dioxygenase in atherosclerotic cardiovascular disease: immune homeostatic mechanisms in the artery wall. Cardiovasc Res. 2019;115(9):1408–1415. doi:10.1093/cvr/cvz067
   PubMed Web of Science ®Google Scholar
• Hao H, Suya Z, Yue C, et al. Analysis of tryptophan-kynurenine pathway in 47 non-dialysis patients with chronic kidney disease[J]. Chin J Kidney Dis Investig. 2020;9(6):247–252.
   Google Scholar
• Lemos H, Huang L, Prendergast GC, et al. Immune control by amino acid catabolism during tumorigenesis and therapy. Nat Rev Cancer. 2019;19(3):162–175. doi:10.1038/s41568-019-0106-z
   PubMed Web of Science ®Google Scholar
• Zhai L, Bell A, Ladomersky E, et al. Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma. Clin Cancer Res. 2021;27(23):6514–6528. doi:10.1158/1078-0432.CCR-21-1392
   PubMed Web of Science ®Google Scholar
• Li Q, Liu J, Fan H, et al. IDO-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironment. Biomaterials. 2021;269:120388. doi:10.1016/j.biomaterials.2020.120388
   PubMed Web of Science ®Google Scholar
• Andersen MH. The T-win® technology: immune-modulating vaccines. Semin Immunopathol. 2019;41(1):87–95. doi:10.1007/s00281-018-0695-8
   PubMed Web of Science ®Google Scholar
• Parra ER, Villalobos P, Zhang J, et al. Immunohistochemical and image analysis-based study shows that several immune checkpoints are co-expressed in non-small cell lung carcinoma tumors. J Thorac Oncol. 2018;13(6):779–791. doi:10.1016/j.jtho.2018.03.002
   PubMed Web of Science ®Google Scholar
• Zheng HJ, Guo J, Wang Q, et al. Probiotics, prebiotics, and synbiotics for the improvement of metabolic profiles in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2021;61(4):577–598. doi:10.1080/10408398.2020.1740645
   PubMed Web of Science ®Google Scholar
• Uchiyama K, Adachi K, Muraoka K, et al. Home-based aerobic exercise and resistance training for severe chronic kidney disease: a randomized controlled trial. J Cachexia Sarcopenia Muscle. 2021;12(6):1789–1802. doi:10.1002/jcsm.12775
   PubMed Web of Science ®Google Scholar
• Niinisalo P, Raitakari OT, Kähönen M, et al. IDO activity forecasts obesity in males and premenopausal females in a 10-year follow-up study: the Cardiovascular Risk in Young Finns Study. Atherosclerosis. 2021;336:32–38. doi:10.1016/j.atherosclerosis.2021.09.018
   PubMed Web of Science ®Google Scholar
• Lu J, Liu X, Liao YP, et al. Breast cancer chemo-immunotherapy through liposomal delivery of an immunogenic cell death stimulus plus interference in the IDO-1 pathway. ACS Nano. 2018;12(11):11041–11061. doi:10.1021/acsnano.8b05189
   PubMed Web of Science ®Google Scholar
• Lukas D, Yogev N, Kel JM, et al. TGF-β inhibitor Smad7 regulates dendritic cell-induced autoimmunity. Proc Natl Acad Sci U S A. 2017;114(8):E1480–E1489. doi:10.1073/pnas.1615065114
   PubMed Web of Science ®Google Scholar
• Correale J. Immunosuppressive amino-acid catabolizing enzymes in multiple sclerosis. Front Immunol. 2021;11:600428. doi:10.3389/fimmu.2020.600428
   PubMed Web of Science ®Google Scholar
• Sharma MD, Pacholczyk R, Shi H, et al. Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity. Immunity. 2021;54(10):2354–2371.e8. doi:10.1016/j.immuni.2021.09.005
   PubMed Web of Science ®Google Scholar